E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
moderate chonic obstructive pulmonary disease (COPD) |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10010952 |
E.1.2 | Term | COPD |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To demonstrate the superiority of indacaterol (150µg o.d.) compared to placebo with respect to Peak Inspiratory Capacity after 21 days of treatment. |
|
E.2.2 | Secondary objectives of the trial |
Key Secondary Objective •To demonstrate the non-inferiority of indacaterol (150µg o.d.) compared to open label tiotropium (18µg o.d.) with respect to Peak Inspiratory Capacity (IC) after 21 days of treatment.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Male and female adults aged ≥ 40 years, who have signed an Informed Consent Form prior to initiation of any study-related procedure 2. Co-operative outpatients with a diagnosis of COPD (moderate as classified by the GOLD Guidelines, 2008) and including: a. Smoking history of at least 10 pack years b. Post-bronchodilator FEV1 < 80% and ≥ 50% of the predicted normal value (Visit 2). c. Post-bronchodilator FEV1/FVC < 70% (Visit 2). (Post refers to within 10-15 min of inhalation of 400μg (4x100 μg) of salbutamol, at Visit 2)
|
|
E.4 | Principal exclusion criteria |
1. Patients who received any Corticosteroid (esp. ICS resp. FDC) for 3 months prior to screening 2. Women who are pregnant or breast feeding and who are menstruating and capable of becoming pregnant and not practicing a medically approved method of contraception (Pearl Index <1**) during and up to at least 4 weeks after the end of treatment. A negative pregnancy test (serum) for all women is required with sufficient lead time before inclusion 3. Patients with a body mass index (BMI) of <15 or >40 kg/m2 4. Patients who have had a COPD exacerbation requiring systemic glucocorticosteroid treatment or antibiotics and/or hospitalization in the 6 weeks prior to screening (Visit 1). In the event of an exacerbation occurring during the run-in period (Visits 1-2), the patient must discontinue from the study. The patient may be re-screened once the inclusion/exclusion criteria have been met 5. Patients requiring oxygen therapy for chronic hypoxemia 6. Patients who have had a respiratory tract infection within 6 weeks prior to Visit 1. Patients who develop a respiratory tract infection between Visit 1 and Visit 2 must discontinue from the trial, but may be re-screened at a later date once the inclusion/exclusion criteria have been met 7. Patients with concomitant pulmonary disease, e.g. pulmonary tuberculosis (unless confirmed by chest x-ray to be no longer active), or clinically significant bronchiectasis 8. Patients with a history (up to and including Visit 2) of asthma indicated by (but not limited to): a. onset of respiratory symptoms (such as cough, wheezing, shortness of breath) suggestive of asthma prior to age 40 years b. history of a diagnosis of asthma 9. Patients with diabetes Type I or uncontrolled diabetes Type II including patients with a history of blood glucose levels consistently outside the normal range or HbA1c > 8.0 % of total hemoglobin measured at Visit 1 10. Patients with contraindications for tiotropium treatment including medical history of symptomatic prostatic hypertrophy, bladder neck obstruction, narrow angle glaucoma and moderate to severe renal impairment (creatinine clearance ≤ 50 mL/min) 11. Patients who, in the judgment of the investigator, have a clinically relevant laboratory abnormality or a clinically significant condition such as (but not limited to) unstable ischemic heart disease, arrhythmia (excluding chronic stable atrial fibrillation) or other clinically significant ECG findings, uncontrolled hypertension and other significant cardiac disease or conduction defect, uncontrolled hypo- and hyperthyroidism, hypokalemia, hyperadrenergic state or any condition which in the opinion of investigator might compromise patient safety or compliance, interfere with evaluation, or preclude completion of the study 12. Patients with lung cancer or a history of lung cancer 13. Patients with active malignancy or a history of malignancy of any organ system 14. Patients with a history (or family history) of long QT syndrome or whose QTc interval (Fridericia) measured at Visit 1 is prolonged: >450 ms (males) or >470 ms (females) 15. Patients with a history of hypersensitivity to any of the study drugs or to drugs from similar drug classes including untoward reactions to sympathomimetic amines or inhaled medication or any component thereof 16. Patients who do not maintain regular day/night, waking/sleeping cycles (e.g. night shift workers) 17. Patients who have had treatment with any investigational drugs at the time of enrollment, or within 30 days or 5 half-lives prior to Visit 2, whichever is longer 18. Patients who have had live attenuated vaccinations within 30 days prior to Visit 2 or during the run-in period. 19. Patients receiving any prohibited medications in the classes listed in Table 6-2 must undergo the required washout period prior to baseline (Visit 2) and follow the adjustment to treatment program. 20. Patients receiving any prohibited COPD related medications in the classes specified in Table 6-3 must undergo the required washout period prior to baseline (Visit 2) and follow the adjustment to treatment program. 21. Patients receiving medications in classes listed in Table 6-4 should be excluded unless the medication has been stabilized for the specified period and the stated conditions have been met 22. Patients unable to successfully use a dry powder inhaler device or perform spirometry measurements 23. Patients with a known history of non-compliance to medication or who are unable or unwilling to complete a Patient Diary themselves. 24. Study personnel or first degree relatives of investigator(s) must not be included in the study.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary objective of the study is to demonstrate that the efficacy of indacaterol is superior to placebo. Following this it should be shown as secondary objective, that indacaterol is not inferior to tiotropium (considering clinical relevance). Then, in a third step, superiority of indacaterol over tiotropium will be tested. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 29 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |